|  |
| --- |
| Supplementary Table 3: Observed complications from 13 to 60 months post-surgery with regards to the affected organsystem. |
| **Complication** | **Overall****na** **(%1; %2)** | **NMIBC****na** **(%1; %2)** | **MIBC****na** **(%1; %2)** | **P-Value** |
| **Follow-up information** |  |  |  |  |
| Complete follow-up  | 138 (26.5) | 48 (39) | 90 (22.6) |  |
| Not available  | 383 (73.5) | 75 (61) | 308 (77.4) |  |
| **Complication y/n, na (%)** | 73 (52.9; 14) | 27 (56.3; 22) | 46 (51.1; 11.6) | 0.565 |
| **Urogenital complications, na (%)** | 20 (14.5; 3.8) | 5 (10.4, 4.1) | 15 (16.7; 3.8) | 0.321 |
| **Infectious complications, na (%)** | 39 (28.3; 7.5) | 14 (29.2; 11.4) | 25 (27.8; 6.3) | 0.863 |
| **Metabolic complications** | 16 (11.6; 3.1) | 8 (16.7; 6.5) | 8 (8.9; 2) | 0.174 |
| **Complications affecting the urinary diversion** | 19 (13.8; 3.6) | 11 (22.9; 8.9) | 8 (8.9; 2) | **0.023\*** |
| **Surgical complications** | 17 (12.3; 3.3) | 7 (14.6; 5.7) | 10 (11.1; 2.5) | 0.554 |
| **Highest complication according to CDC** |  |  |  | 0.369 |
| CDC grade I, na (%) | 8 (5.8; 1.5) | 3 (6.3; 2.4) | 5 (5.6; 1.3) |  |
| CDC grade II, na (%) | 33 (23.9; 6.3) | 15 (31.3; 12.2) | 18 (20; 4.5) |  |
| CDC grade IIIa, na (%) | 1 (0.7; 0.2) | 0 (0; 0) | 1 (1.1; 0.3) |  |
| CDC grade IIIb, na (%) | 30 (21.7; 5.7) | 10 (20.8; 8) | 20 (22.2; 5) |  |
| CDC grade IVa, na (%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) |  |
| CDC grade IVb, na (%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) |  |
| CDC grade V, na (%) | 1 (0.7; 0.2) | 0 (0; 0) | 1 (1.1; 0.3) |  |
| **Total number of complications (n/patient), median (IQR)** | 1 (1-3) | 2 (1-3) | 1 (1-2) | 0.132 |
| **Revision surgery** |  |  |  |  |
| Revision surgery y/n, na (%) | 32 (23.2; 6.1) | 10 (20.8; 8.1) | 22 (24.4; 5.5) | 0.608 |
| Amount (n/patient), median (IQR) | 2 (1-3) | 2 (1-2) | 2 (1.3) | 0.162 |
| Ureterocystoneostomy, na (%) | 1 (0.7; 0.2) | 1 (2.1; 0.8) | 0 (0; 0) | 0.350 |
| Hernia / Ileus / Lymphocele / Fistula, na (%) | 10 (7.2; 1.9) | 4 (8.3; 3.3) | 6 (6.7; 1.5) | 0.733 |
| Incision urethra / bladder neck, na (%) | 4 (2.9; 0.8) | 2 (4.2; 1.6) | 2 (2.2; 0.5) | 0.524 |
| Urinary diversion, na (%) | 4 (2.9; 0.8) | 1 (2.1; 0.8) | 3 (3.3; 0.8) | 0.669 |
| Nephrostomy / ureteral stent, na (%) | 15 (10.9; 2.9) | 2 (4.2; 1.6) | 13 (14.4; 3.3) | 0.062 |
| Revision due to incontinence, na (%) | 2 (1.4; 0.4) | 1 (2.1; 0.8) | 1 (1.1; 0.3) | 1.000 |
| \* Indicates statistical significance.  |
| a Numbers reflect the number of patients. |
| 1 Numbers reflect percentages with regards to patients with full follow-up. |
| 2 Numbers reflect percentages with regards to the overall population. |
| NMIBC = non-muscle-invasive Bladder Cancer, MIBC = muscle-invasive Bladder Cancer, IQR = Interquartile Range, CDC = Clavien-Dindo-Classification. |